Pacific Biosciences of California, Inc. cash flow to debt ratio of -14.64% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Pacific Biosciences of California, Inc.'s free cash flow has increased -46.33% from $-212.25M last year to $-113.92M, signaling increasing performance

Pacific Biosciences of California, Inc.'s debt to equity ratio is -21.26, signaling that the company spent its equity and risk bankruptcy.

Pacific Biosciences of California, Inc.'s debt to equity ratio is -21.26, signaling that the company spent its equity and risk bankruptcy.

Pacific Biosciences of California, Inc. has negative EBITDA, making leverage ratio unreliable

Pacific Biosciences of California, Inc.'s interest coverage ratio is -42.23, which means that the company struggles to meet interest obligations, signaling financial risk.

Pacific Biosciences of California, Inc.'s profit margin has increased (-59.00%) in the last year from -201.18% to -82.49%, signaling increasing performance

Pacific Biosciences of California, Inc.'s short-term assets of $375.03M exceed its short-term liabilities of $54.42M

Pacific Biosciences of California, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Pacific Biosciences of California, Inc.'s return on equity of -4.96K%, is lower than 15.00%, indicating bad performance

Pacific Biosciences of California, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Pacific Biosciences of California, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Pacific Biosciences of California, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Pacific Biosciences of California, Inc. has negative free cash flow, indicating cash burn

Pacific Biosciences of California, Inc.'s yearly earnings has decreased 76.34% since last year from $-309.85M to $-546.38M, signaling decreasing performance

Pacific Biosciences of California, Inc.'s yearly revenue has increased 3.89% since last year from $154.01M to $160.00M, signaling increasing performance

ROIC -23.75% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Pacific Biosciences of California, Inc.'s 3-year revenue CAGR of 7.64% is positive, indicating growing revenue over the past 3 years

Pacific Biosciences of California, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Pacific Biosciences of California, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Pacific Biosciences of California, Inc. has insufficient data to evaluate this check.

Pacific Biosciences of California, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pacific Biosciences of California, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Pacific Biosciences of California, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Pacific Biosciences of California, Inc. is overvalued relative to its fair value price of -24.72 based on Earnings Fair Value model

Pacific Biosciences of California, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pacific Biosciences of California, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Pacific Biosciences of California, Inc. has a price-to-sales ratio of 2.24x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue